May 25th is a day well worthy of our celebration and commemoration. After a year¡¯s efforts of all staff, the sub-unit influenza vaccine eventually gained production license approved by SFDA. Interlong is the first approved manufacturer of sub-unit influenza vaccine with own technique in China, which marks a periodical victory for Neptunus Interlong.
Sub-unit influenza vaccine is a common use and wildly accepted 3rd generation flu vaccine, which features in well protective antigen and less side effect when compared to previous influenza whole virion vaccine and influenza split virion vaccine. At the present day, this kind of vaccine still depends on imports due to only few advanced country owing this technique. We have developed the sub-unit influenza vaccine since 2003, brought in new technique and built up GMP plant with capacity of producing 10 million doses which is in accordance with international advanced standards. Thanks to the international advanced technology, high technique standards to whole production and quality control process, and also concerted efforts of our whole staff, scaling up trial-production to GMP plant production is completed successfully. Three batches of trial products were submitted and tested to be in accordance with quality standards, SFDA eventually granted us Drug Production License No. on May 25th after strict examination and scrutinizing.
We will seize this opportunity and make concerted efforts to further develop more and better products, dedicated ourselves to human health. |
Your
Current position:
